Dyne therapeutics logo
WebOct 1, 2024 · Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).
Dyne therapeutics logo
Did you know?
WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. WebMar 2, 2024 · Dyne Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39509 36-4883909 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number ...
WebDec 15, 2024 · The Trade: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million. What ... WebOct 4, 2024 · Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with …
WebMay 7, 2024 · Dyne Therapeutics' cash burn of US$59m is about 6.4% of its US$916m market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a ... WebMay 14, 2024 · In January 2024, Dyne reported data showing that two doses (2 x 10 mg/kg) of its lead DM1 candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days. New data being presented ...
WebApr 12, 2024 · Dyne Therapeutics 7,990 followers 14h Report this post Report Report. Back Submit. Exciting news for the ...
WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … high end executive conference room tablesWebApr 3, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched today with a $50 million Series ... high end evil eye jewelryWebJan 14, 2024 · --Dyne Therapeutics, Inc., a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S ... high end expertWebApr 13, 2024 · What's Happening With Dyne Therapeutics Inc Stock Today? Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of … high end extruded hollow vinyl fenceWebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... high end fabricWebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务,查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息,想了解Dyne Therapeutics Inc.怎么样,就 ... high end experiencesWebDyne Therapeutics is registered under the ticker NASDAQ:DYN . Their stock opened with $19.00 in its Sep 16, 2024 IPO. Dyne Therapeutics is funded by 9 investors. Logos … high end eyeglass frame brands